The Medicines Patent Pool (MPP) has announced a new, royalty-free licence agreement with AbbVie for glecaprevir/pibrentasvir (G/P) – a World Health Organization (WHO)-recommended treatment for people living with chronic hepatitis C (HCV).

A second-line HIV regimen containing the integrase inhibitor raltegravir failed to meet its primary endpoint of noninferiority against standard second-line treatment with nucleoside reverse-transcriptase inhibitors, or NRTIs, according to 144-week data from the EARNEST trial.